Last reviewed 2026-04-23 · How we verify

ATR-002 MEK Inhibitor

Atriva Therapeutics GmbH · Phase 1 active Small molecule

ATR-002 MEK Inhibitor is a MEK inhibitor Small molecule drug developed by Atriva Therapeutics GmbH. It is currently in Phase 1 development for Non-small cell lung cancer. Also known as: PD01842649.

MEK inhibitor

MEK inhibitor Used for Non-small cell lung cancer.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ATR-002 MEK Inhibitor
Also known as	PD01842649
Sponsor	Atriva Therapeutics GmbH
Drug class	MEK inhibitor
Target	MEK
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 1

Mechanism of action

Inhibits the activity of MEK enzymes, which are involved in the MAPK/ERK signaling pathway.

Approved indications

Non-small cell lung cancer

Common side effects

Diarrhea
Nausea
Vomiting

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ATR-002 MEK Inhibitor CI brief — competitive landscape report
ATR-002 MEK Inhibitor updates RSS · CI watch RSS
Atriva Therapeutics GmbH portfolio CI

Frequently asked questions about ATR-002 MEK Inhibitor

What is ATR-002 MEK Inhibitor?

ATR-002 MEK Inhibitor is a MEK inhibitor drug developed by Atriva Therapeutics GmbH, indicated for Non-small cell lung cancer.

How does ATR-002 MEK Inhibitor work?

MEK inhibitor

What is ATR-002 MEK Inhibitor used for?

ATR-002 MEK Inhibitor is indicated for Non-small cell lung cancer.

Who makes ATR-002 MEK Inhibitor?

ATR-002 MEK Inhibitor is developed by Atriva Therapeutics GmbH (see full Atriva Therapeutics GmbH pipeline at /company/atriva-therapeutics-gmbh).

Is ATR-002 MEK Inhibitor also known as anything else?

ATR-002 MEK Inhibitor is also known as PD01842649.

What drug class is ATR-002 MEK Inhibitor in?

ATR-002 MEK Inhibitor belongs to the MEK inhibitor class. See all MEK inhibitor drugs at /class/mek-inhibitor.

What development phase is ATR-002 MEK Inhibitor in?

ATR-002 MEK Inhibitor is in Phase 1.

What are the side effects of ATR-002 MEK Inhibitor?

Common side effects of ATR-002 MEK Inhibitor include Diarrhea, Nausea, Vomiting.

What does ATR-002 MEK Inhibitor target?

ATR-002 MEK Inhibitor targets MEK and is a MEK inhibitor.

Drug class: All MEK inhibitor drugs
Target: All drugs targeting MEK
Manufacturer: Atriva Therapeutics GmbH — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Non-small cell lung cancer
Also known as: PD01842649

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing